These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 36424083)
1. Urine-Based Markers for Detection of Urothelial Cancer and for the Management of Non-muscle-Invasive Bladder Cancer. Lotan Y; Baky FJ Urol Clin North Am; 2023 Feb; 50(1):53-67. PubMed ID: 36424083 [TBL] [Abstract][Full Text] [Related]
5. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. Mbeutcha A; Lucca I; Mathieu R; Lotan Y; Shariat SF Urol Clin North Am; 2016 Feb; 43(1):47-62. PubMed ID: 26614028 [TBL] [Abstract][Full Text] [Related]
6. Current Use and Promise of Urinary Markers for Urothelial Cancer. Tabayoyong W; Kamat AM Curr Urol Rep; 2018 Oct; 19(12):96. PubMed ID: 30328534 [TBL] [Abstract][Full Text] [Related]
7. Urinary markers in the everyday diagnosis of bladder cancer. Dal Moro F; Valotto C; Guttilla A; Zattoni F Urologia; 2013; 80(4):265-75. PubMed ID: 24419920 [TBL] [Abstract][Full Text] [Related]
8. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Kumar A; Kumar R; Gupta NP Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358 [TBL] [Abstract][Full Text] [Related]
9. Urine Cytology Rarely Escalates Clinical Management in the Surveillance of Non-muscle-Invasive Bladder Cancer. Feiertag N; Barry E; Abramson M; Park JY; Kovac E; Aboumohamed A; Watts K; Sankin A Clin Genitourin Cancer; 2023 Apr; 21(2):258-264. PubMed ID: 36621462 [TBL] [Abstract][Full Text] [Related]
10. Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation. Terrell JD; Elias KJ; Sagalowsky AI; Lotan Y Int Braz J Urol; 2011; 37(6):706-11. PubMed ID: 22234001 [TBL] [Abstract][Full Text] [Related]
11. [Non-invasive urinary diagnosis of bladder cancer. What do we know?]. Kausch I; Böhle A Urologe A; 2003 Jul; 42(7):912-21. PubMed ID: 12898034 [TBL] [Abstract][Full Text] [Related]
12. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. Herman MP; Svatek RS; Lotan Y; Karakiewizc PI; Shariat SF Minerva Urol Nefrol; 2008 Dec; 60(4):217-35. PubMed ID: 18923359 [TBL] [Abstract][Full Text] [Related]
13. [Diagnosis of urothelial carcinoma]. Karl A; Zaak D; Tilki D; Hungerhuber E; Staehler M; Denzinger S; Stanislaus P; Tritschler S; Strittmatter F; Stief C; Burger M Urologe A; 2008 Mar; 47(3):357-67. PubMed ID: 18274722 [TBL] [Abstract][Full Text] [Related]
14. A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria. Dahmcke CM; Steven KE; Larsen LK; Poulsen AL; Abdul-Al A; Dahl C; Guldberg P Eur Urol; 2016 Dec; 70(6):916-919. PubMed ID: 27417036 [TBL] [Abstract][Full Text] [Related]
16. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine. Golijanin D; Sherman Y; Shapiro A; Pode D Urology; 1995 Aug; 46(2):173-7. PubMed ID: 7624989 [TBL] [Abstract][Full Text] [Related]
17. Voided urine versus bladder washing cytology for detection of urothelial carcinoma: which is better? Keller AK; Jensen JB Scand J Urol; 2017 Aug; 51(4):290-292. PubMed ID: 28398114 [TBL] [Abstract][Full Text] [Related]
18. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers. Zuiverloon TCM; de Jong FC; Theodorescu D Oncology (Williston Park); 2017 Dec; 31(12):855-62. PubMed ID: 29297169 [TBL] [Abstract][Full Text] [Related]
19. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000 [TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]